Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom

Overview of attention for article published in HEPAC Health Economics in Prevention and Care, March 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)

Mentioned by

policy: 1 policy source
twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 117 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,227 followers.

Movement Disorders in Children https://t.co/8P5aR3E2iS #eprompt #paedmed

Reply Repost Favourite

Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in CU - PubMed - NCBI https://t.co/B82wS65vUJ

Reply Repost Favourite

#HealthEconJA Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients wi… https://t.co/SNlmysBGQv

Reply Repost Favourite